In a publication written in August 2021, scientists Rabanel et al. from the INRS Centre Armand-Frappier Santé Biotechnologie and the Université de Montréal sought to tackle a fundamental challenge in developing pharmaceutical interventions for a variety of brain disorders: delivering drugs across the blood brain barrier (BBB). Their solution involved novel zwitterion polymer coated (PMPC) nanoparticles which they compared to more widely used PEGlyated nanoparticles. Both were synthesized using the NanoAssemblr® microfluidic mixing platform. In vitro assays using mouse neuronal and macrophage cell lines reveal a higher internalization through active endocytosis mechanisms of PMPC-coated NPs compared to PEGylated NPs. For microglia and macrophage cell lines, PMPC-coated NPs demonstrate a 10-fold higher capture and showcase efficient translocation in neuronal in vitro BBB models. On the other hand, in vivo experiments using zebrafish larvae in this paper illustrate strong associations of PMPC-coated NPs with the vascular endothelium along with shorter circulation time in comparison to PEGylated NPs. In conducting this study, further developments in brain targeted drug delivery, such as the use of PMPC-coats and inclusion of protein components in nanoparticle structure, can assist in addressing chronic neurodegenerative diseases.